Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Reduced Net Loss of $19.9M in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025, Down from $26.2M in Q2 2024; R&D Expenses Decrease to $12.9M
Seres Therapeutics Inc. has reported its financial results for the second quarter of 2025. The company experienced a net loss from continuing operations of $19.9 million, which is an improvement compared to a net loss of $26.2 million for the same period in 2024. Research and development expenses also decreased to $12.9 million in the second quarter of 2025 from $15.8 million in the same period of the previous year. This reduction was largely attributed to a decrease in expenses following the completion of the SER-155 Phase 1b study, reduced personnel and related expenses, and lower platform investments. In terms of business updates, Seres has submitted a Phase 2 study protocol to the FDA for SER-155, aimed at preventing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant to treat hematological malignancies. The company is actively exploring various deal structures, including partnerships and mergers, to secure capital for the clinical advancement of SER-155 and other live biotherapeutic product candidates. Additionally, Seres received a $25 million installment payment from Nestlé Health Science in July 2025. The company expects to fund its operations into the first quarter of 2026, following cost reduction actions aimed at extending its cash runway.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-173985), on August 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.